Osteosarcoma1999-A Study Of Intensive Chemotherapy for Osteosarcoma
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
This trial (OS99) evaluates the use of ifosfamide, carboplatin, and doxorubicin in an
up-front window before surgery for localized and resectable osteosarcoma. High-dose
methotrexate, which may interfere with the dose-intensive delivery of other agents, is
eliminated from the treatment of localized disease. The primary objective is to compare the
response rate of pre-surgical chemotherapy comprised of ifosfamide, doxorubicin, and
carboplatin to that obtained with ifosfamide and carboplatin in the St. Jude OS-91 trial for
patients with non-metastatic resectable osteosarcoma. We hypothesize that the histologic
response rate will be improved by the addition of one course of pre-operative chemotherapy on
this trial compared to the previous OS-91 trial.
Phase:
Phase 2
Details
Lead Sponsor:
St. Jude Children's Research Hospital
Collaborators:
Immunex/Berlex National Institutes of Health (NIH)